SAN DIEGO, April 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, today announced details relating to its first quarter 2005 earnings announcement, which will take place on Tuesday, April 26, 2005, after the close of the Nasdaq.
NuVasive will hold a conference call at 5:00 p.m. EDT / 2:00 p.m. PDT to discuss the results. The dial-in numbers are 1-800-819-9193 for domestic callers, and 1-913-981-4911 for international. The reservation number for both is 4679466. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com .
After the live Web cast, the call will remain available on NuVasive's Web site, http://www.nuvasive.com , through May 26, 2005. In addition, a telephonic replay of the call will be available until May 17, 2005. The replay dial-in numbers are 1-888-203-1112 for domestic callers and 1-719-457-0820 for international callers. Please use reservation code 4679466.
We are a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. Our product portfolio is focused on applications in the over $2 billion U.S. spine fusion market. Our current principal product offering includes a minimally disruptive surgical platform that we call Maximum Access Surgery, or MAS, as well as classic fusion products. MAS combines three categories of our current product offerings-NeuroVision, a proprietary software-driven nerve avoidance system, MaXcess, a split blade-design minimally invasive surgical system and specialized implants-that collectively minimize soft tissue disruption during spine surgery. Our classic fusion portfolio is comprised predominantly of spine allografts, which are human bone that has been processed and precision shaped for transplant and metal mesh cages. The majority of our currently marketed products have been cleared by the FDA.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, the rapidly changing and competitive nature of the medical device industry, NuVasive's ability to convince surgeons to use its products, the ability of patients to obtain third-party reimbursement for surgical procedures employing NuVasive's products, risks related to government regulation of medical devices, risks related to NuVasive's ability to effectively manage the growth of its business, risks related to ownership and enforcement of intellectual property rights, NuVasive's ability to successfully develop new products, and other risks and uncertainties more fully described in NuVasive's Annual Report on Form 10-K filed with the Securities and Exchange Commission and NuVasive's Prospectus filed pursuant to Rule 424 under the Securities Act of 1933. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov . NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Contact: Investors: Kevin C. O'Boyle Stephanie Carrington/Nick Laudico Chief Financial Officer The Ruth Group NuVasive, Inc. 646-536-7017/7030 858-909-1800 firstname.lastname@example.org email@example.com firstname.lastname@example.org
SOURCE NuVasive, Inc.
Kevin C. O'Boyle,
Chief Financial Officer, NuVasive, Inc.,
both of The Ruth Group for NuVasive, Inc.